BANGALORE: A medical invention by a Bengalore-based scientist, Rajah Vijay Kumar, has been labelled as a “breakthrough device” by the US Food and Drug Administration (FDA)’s Centre for Devices and Radiological Health, said a Times of India report.
The device called Cytotron was created to cure liver, pancreatic and breast cancer. The device provides non-invasive tissue engineering that can help treat solid tumours. It is also found to be useful in pain relief and palliative care.
“We are pleased to inform you that your device and proposed indication for use meet the criteria and have been granted designation as a breakthrough device,” states a communique from the FDA wing to Shreis Scalene Sciences, the company that had taken the device to the US.
“It is indicated for treating protein-linked, abnormally regenerating disorders such as neoplastic disease, and allowing extended progression free survival, with pain palliation, improved quality and dignity of life,” says the letter as quoted by the TOI.
Generically known as rotational field quantum magnetic resonance, Cytotron uses fast radio bursts (FRB), high energy and powerful short radio bursts in which both electric and magnetic components of the electromagnetic signals are "circularly" polarised.
FRBs are produced when a radio signal travels through a powerful instantaneous magnetic field on its path to the target. “FRBs can be used to communicate with the cellular command and control, to up or down regulate a specific protein or gene,” Kumar said in a statement.
“In cancer cells, Cytotron does two things: First, it alters the protein pathways of a proapoptosis protein called p53 via p21 inducing programmed cell death in the cancer cells. Second, exposure to Cytotron stops metastasis by inhibiting the epithelial mesenchymal transition cells, responsible for spread of cancer; 90% cancer patients die due to metastasis,” the TOI report quoted Kumar as saying.
Kumar had developed Cytotron, based on quantum magnetic resonance therapy (QMRT), at the Bhopal-based Centre for Advanced Research and Development after nearly 30 years of research into cellular pathways.
“It is a great feeling that after so many years of hard work, against all odds, an institution like the USFDA is designating our work as a breakthrough in the treatment of three types of cancers,” Kumar was quoted by Times of India as saying.
He pointed out that new technologies in the battle against cancer have generally been hard to come by. It’s even rarer for an Indian device to get breakthrough status in the US.
“The devices will all be made in India, given that there are hardly any imported components. And our American partner will take the device to the US. Cytotron is already an approved medical device and is in use in the UAE, Mexico, Malaysia and Hong Kong, among others,” Kumar said.
Image Credit: Health Vision India